

Financial Tear Sheet

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$18.90
Change (%)	▼ 0.55 (2.83%)
Volume	319,608
52 Week Low	\$9.80
Market Cap	\$524,686,453
Rolling EPS	-3.82
PE Ratio	N/A
Shares Outstanding	27,761,188
Data as of 08/21/17 4:00 p.m. ET	



Recent Paratek Pharmaceuticals News & Events

08/08/17 - 8:00 a.m.

Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference

There are currently no events scheduled.

08/02/17 - 7:00 a.m.

Paratek Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results and Provides Clinical Update

08/01/17 - 8:01 a.m.

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SEC Filings

Filing Date	Form
-------------	------

08/04/17	8-K
----------	-----

08/02/17	10-Q
----------	------

07/21/17	4
----------	---

07/21/17	4
----------	---

Management

Randy Brenner Senior Vice President -
Regulatory, Quality and
Technical Operations

Jason Burdette Vice President -
Technical Operations

Jeanne Jew Senior Vice President -
Business Development

Raj Padmanabhan Vice President -
Information Technology

Regina Paglia Senior Vice President -
Human Resources

Susan Perkins,
J.D. Vice President -
Intellectual Property

Evan Tzanis Senior Vice President -
Clinical Development &
Clinical Operations

Michael F. Bigham Chief Executive Officer
and Chairman of the
Board

Evan Loh, M.D. President, Chief
Operating Officer and
Chief Medical Officer

William Haskel General Counsel and
Corporate Secretary

Douglas W. Pagán Chief Financial Officer

Adam Woodrow Chief Commercial Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.